Loading...
Glucagon-like peptide-1 receptor agonists are a revolutionary class of peptides researched for metabolic regulation, appetite control, and glucose homeostasis. These compounds mimic or enhance the effects of the naturally occurring incretin hormone GLP-1, with applications spanning weight management, type 2 diabetes, and cardiovascular health.
An earlier GLP-1 receptor agonist approved for diabetes and weight management, offering once-daily dosing with proven efficacy and safety.
View detailsA once-weekly GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, representing a breakthrough in metabolic medicine with average weight loss of 15-17% in clinical trials.
View detailsA first-in-class dual GLP-1 and GIP receptor agonist achieving unprecedented weight loss of up to 22% in clinical trials, approved for type 2 diabetes and obesity treatment.
View detailsAn investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, showing unprecedented weight loss of up to 24% in Phase 2 trials—potentially the most potent obesity treatment in development.
View details